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Abstract Lymphangioleiomyomatosis (LAM), characterized by alveolar smooth muscle proliferation and cystic de-
struction of lung parenchyma, can occur as a rare sporadic disease or as a complication of tuberous sclerosis (TSC). It is
a cystic lungdisease, usuallygeneralized andprogressive, maybe extremelydi⁄cultto treat andhas been considered to
have a poorprognosis.It has almostexclusivelybeenreported topresent inwomenofchildbearingage, mostcommonly
with dyspnoea andpneumothorax.Wereviewed the English literature from1939 to1997 forcases of LAMbothwith and
without TSC, in order to documentthe prevalence, clinical features, investigations, treatment and outcomewithin and
between these two groups.No study has yet determined the prevalence of LAM symptomatically within the general
population, but it probably a¡ects1^3% oftheTSCpopulation.PatientswithTSCoftenpresentwith aninsidious onsetof
dyspnoeawhilst non-TSCpatients presentmore commonly with acute breathlessness secondary to pneumothorax. Pa-
tients withTSC are also less likely to su¡er from chylothorax.The age of onset of symptoms and of diagnosis are similar.
LAMis rare in children and even less common inmales in both groups.The natural course of LAMremains unclear and
e¡ect of treatment variable. Although symptomatic LAM is uncommon it causes a signi¢cant amount of morbidity
andmortalitybothintheTSCandgeneralpopulation, but asymptomatic LAMisnotuncommoninTSC.Further research
is required to determine the natural history of this condition and to evaluate current treatment regimes. r 2001Harcourt
Publishers Ltd
doi:10.1053/rmed.2001.1207, available online at http://www.idealibrary.comon
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Lymphangioleiomyomatosis (LAM) occurs in association
with tuberous sclerosis (TSC) or arises as a single entity.
Its pathogenesis remains uncertain butmay have amole-
cular genetic basis. Hamartomas (including lymphangio-
leiomyomas) arising in individuals with TSC involve
tumour suppressor genes with inactivation of both al-
leles of TSCI or TSC2 through a germline or early
embryonic mutation and a second ‘somatic’ mutation of
the remaining normal gene. A chance double ‘somatic’
inactivation of both alleles of oneTSC gene in an indivi-
dual without a germline mutation could explain the
occurrence of LAM in an individual with no other signs
of TSC.Received 3 July 2001, accepted13 August 2001and published online14
November 2001.
Correspondence should be addressed to: Prof. John Osborne,The
Children’s Centre, Royal United Hospital,Combe Park, Bath BAI 3NG,
U.K.Fax: 01225-824212;E-mail: mpsjpo@bath.ac.ukLAM predominately a¡ects females of childbearing
age (1) and is characterized by alveolar smooth muscle
proliferation and cystic destruction of the normal lung
parenchyma.The commonest presenting symptoms are
dyspnoea from pneumothorax and chylothorax, but
other symptoms include chronic cough, haemoptysis,
wheeze and chest pain.Cyanosis, respiratory failure and
cor pulmonale can occur (1^3), but asymptomatic cases
have been described (2). Pulmonary function tests can
show an obstructive or restrictive pattern (4).
Treatment of LAM is di⁄cult, and it has historically
been symptomatic: by drainage of pneumothoraces, use
of conventional inhalers for wheeze and oxygen therapy
for respiratory failure.More recently, hormone manipu-
lation has been tried but without consistent success
(3,5). The long-term prognosis is considered poor with
many patients thought to follow a relentless deteriora-
tion after the onset of their symptoms (2).
The aims of this study were to document the
incidence, prevalence, sex, age, presenting features,
2 RESPIRATORYMEDICINEinvestigations, treatment and outcome of LAM arising in
patients ‘de novo’ and in those with a diagnosis of TSC
through a comprehensive review of the literature. Also
to compare the ¢nding of these groups and highlight the
similarities and di¡erences between them.
METHODS
A search of the English literature for all cases of LAM,
both with and without associated TSC, was performed
from 1939 to 1997 using the Medline and Embase data-
bases. The references of all retrieved papers (including
those discounted after review) were searched for addi-
tional references.
The cases were then divided into three groups on the
following criteria.TSC: a diagnosis of TSCwas stated by
the authors, or the authors reported features in the in-
dividual(s) which ful¢lled contemporary criteria for the
diagnosis of TSC (6). Not TSC: the authors stated that
the individual(s) did not have any features of TSC.
Unknown: the authors did not state whether the indivi-
dual(s) did or did not haveTSC, features suggesting pos-
sible TSC may have been described (e.g. mental
retardation) but did not ful¢l the criteria for a diagnosis
of TSC.This last groupwas then excluded from analysis.
RESULTS
Therewere183 papers citing a total of 445 cases of LAM.
Eighty-three cases had TSC, 69 did not haveTSC. In 293
patients it was not clear if TSCwas present or excluded.
In total there were only 10 studies that presented
a cohort of patients (8^46 patients). The remaining
papers only presented case studies. No study gave an
overall estimation of either the incidence or prevalence
of LAM in the general population.Two studies did how-
ever give an estimation of the prevalence of LAM in pa-
tients with TSC. Castro et al. (3) undertook a
retrospective studyover 43 years (1948^1991) of patients
attending theMayo clinic; 388 patients had TSC andnineTABLE 1 Details ofmaleswith apparent LAM.Innonewas the ¢
TSC
Case onehad chest X-ray ¢ndings compatiblewith a diagnosis of
Case twohad chest X-ray ¢ndings thatwerenottypical of LAMa
possible thatthis patientdidnothave LAM
Case three had ¢ndings typical of LAMonhis chest X-ray, butthe
smoothmuscle proliferation
Case fourwas shownto have cysts, both emptyand ¢lled on biop
Case ¢ve a normal HRCTwasreported
Not TSC
This case onlyhad a‘clinical diagnosis’of LAMwithno pathologicaof these had LAM diagnosed, giving a prevalence of
B2?3%.Dwyeret al. (2) gave an estimated prevalence of
less than1%, but they did not say how they reached this
conclusion.
There were 435 females, nine males and in one case
the gender was not given. Seventy-eight females and ¢ve
maleshad TSC, and 68 females and onemalewere stated
as not havingTSC. In none of the males in whom LAM
was reported were the accounts fully consistent with a
diagnosis of LAM (seeTable1).The average age of onsetof
pulmonary symptoms in the group withTSC was given
for 75 patients, mean 30.4 years (range 8^57 years, SD
9?2 years). In the patients without TSC, it was given for
68 cases, mean 34?6 years (range 9^62 years, SD 11?9
years). The age of diagnosis of LAM in the group with
TSC was given for 59 patients, mean 36?6 years
(range 13^72 years, SD 10?7 years). In the group without
TSC, it was given for 29 cases mean 36?6 years
(range 8^68 years, SD 12?7 years). The di¡erences were
not signi¢cant.
The symptoms experiencedby each of the two groups
and their presenting features are summarized inTable 2.
Patients who were known to haveTSCweremore likely
to present with gradual onset of dyspnoea, whilst those
not havingTSCweremore likely to present with a pneu-
mothorax. The commonest reported complications
were pneumothorax and chylothorax, this latter being
more common in those without TSC. Pleural e¡usions
were also reported but it was not always stated if these
were serous, chylous or bloody. Patients withTSCwere
muchmore likely to be asymptomatic.
Not all papers stated how a diagnosis of LAM was
con¢rmed but there was no di¡erence in the method of
diagnosis used between the two groups (Table 2). Lung
function testing was much less likely to have been per-
formed in those patients known to haveTSC.No patient
withTSC had a mixed picture of obstructive and restric-
tive impairment compared with 48% of the non-TSC
group (Table 2).
Where statedmost patients were treated symptoma-
tically.Pnuemothoraces ande¡usionswere drainedwhenndings convincing bymodern standards
LAMand a biopsyreported‘as consistentwithTSC’
ndhadnothad CTor biopsyperformed.It is therefore
authors didnot statewhether the biopsy showed
sy, butnomention of smoothmuscle proliferation
l con¢rmation
TABLE 2 Symptoms andpresenting features, investigations and treatmente¡ects of patientswith LAMandwith orwithout TSC
TSCn = 83 Not TSCN= 69
Symptoms experienced and symptoms at presentation
Dyspnoea any time: 67% 91%
Dyspnoea at presentation: 38% 20%
Pneumothorax any time: 47% 67%
Pneumothorax at presentation: 29% 68%
Cough any time: 24% 35%
Cough atpresentation: 0% 0%
Chylothorax any time: 10% 33%
Chylothorax at presentation: 2% 2%
Haemoptysis any time: 19% 32%
Haemoptysis at presentation: 0% 3%
Respiratory failure any time: 0% 0%
Respiratory failure at presentation: 0% 2%
Pain (withoutprovenpnuemothorax) any time: 6% 2%
Pain (withoutprovenpnuemothorax) at presentation: 0% 0%
Other any time: 2% 3%
Other at presentation: 6% 2%
Asymptomatic 25% 3%
Investigations (for diagnosis)
Postmortem 9 (10%) 8 (12%)
Biopsy 18 (21%) 16 (23%)
Chest CT 15 (18%) 7 (10%)
Chest X-ray 9 (10%) 4 (6%)
Notreported 32 (39%) 34 (49%)
Pulmonary function tests
Normal 5(6%) 4 (6%)
Obstructive 18 (22%) 16 (23%)
Restrictive 3 (4%) 1 (1%)
Mixed 0 33 (48%)
Abnormal 8 (10%) 2 (3%)
Notreported 49 (59%) 13 (19%)
Patientswho didundergo hormonalmanipulation
Improved 6 (33%) 2 (5%)
Stable/unchanged 5 (27%) 9 (21%)
Worsened/died 6 (33%) 23 (55%)
Unknown 1 (5%) 8 (19%)
Total 18 42
Average followup 5 years 8 years
Patientswho didnot undergo hormonalmanipulation
Improved 0 1 (7%)
Stable/unchanged 6 (24%) 3 (20%)
Worsened/died 19 (76%) 11 (73%)
Total 25 15
Average follow-upnotgiven for this as data not available
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were frequently reported. Many patients received
courses of antibiotics and those in respiratory failure
were treated with oxygen. Hormonal manipulation (in-
cluding methylprogesterone, tamoxifen, surgical oo-
phorectomy, radioablation of the ovaries, buserelin and
LHRH)was triedin a total of 60 (39%) patientswith vari-
able success. Follow-up was only reported for 40 (26%)
patients who did not receive hormonal treatment (Table
2). Although the trend is that patients undergoing hor-monal manipulation (especially those with TSC) had a
better outcome than those who did not, the numbers
are too small for analysis.
DISCUSSION
Although we divided patients into those who had a de¢-
nite diagnosis of TSC and thosewho did not haveTSC as
de¢nedin themethods,we assumed that the diagnosis of
4 RESPIRATORYMEDICINELAMwas correct in all cases but it was not always clear
as to how this diagnosiswas reachedor howunequivocal
the diagnosis was and some cases are likely to have been
misdiagnosed.
Although LAM predominately a¡ects females of child-
bearing age, cases occurring in men (7,8) and children
(9,10) have, rarely, been reported. In many cases symp-
toms are exacerbated during the menstrual cycle or in
the course of a pregnancy (11,12), and patients have also
reported onset of symptoms following the menopause
(13,14), or after commencing the oral contraceptive pill
(3). It is di⁄cult to estimate the true frequency of LAM
in males. It is certainly extremely rare. In any male in
whom the diagnosis is suspected, other pulmonary diag-
noses must be excluded and the gender should be con-
¢rmed by karyotype to rule out Kleinfelter’s syndrome.
Male patients should have HRCT and lung biopsy per-
formed to con¢rm the diagnosis.
Although there was no di¡erence between the two
groups for average age of onset of pulmonary symptoms
and age at diagnosis of LAM, there was a shorter period
of delay between onset and diagnosis in the group with-
out TSC.Onemight expect to make the diagnosis quick-
er in patientswithTSC because of heightened awareness
of the possibility of LAM in TSC. Patients who were
known to haveTSCweremore likely to presentwith gra-
dual onset of dyspnoea, whilst those not having TSC
were more likely to present with a pneumothorax.One
possible explanation for this might be that patients with
TSC aremore likely to develop multiple foci of LAM be-
cause of their genetic predisposition. As these area
slowly increase in both number and size causing destruc-
tion of the normal lung parenchyma they result in in-
creasing dyspnoea which is inversely proportional to
thevolume of normal lung remaining. In patientswithout
TSC a single harmatoma arising as a chance event may
remain asymptomatic with the remaining normal lung
parenchyma compensating for the single area of abnorm-
ality until there is a sudden pneumothorax.No study has
reported radiographic imaging to correlate between the
size, position or number of the harmatomas and the in-
cidence of pneumothorax.Chylothoracesmay occur less
commonly inpatientswithTSC; 10%of caseswithproven
TSC compared to 33% in patients inwhomTSC has been
de¢nitely excluded. A possible explanation is found his-
tiologically, as the smooth muscle proliferation in LAM
seen inTSC ismore frequently described as being predo-
minantly perivascular, whilst in LAM without TSC it is
more often described as perilymphatic (3). The reason
for the di¡erent distribution is not clear. The increased
awareness of LAM inTSCmight explain the higher num-
ber of asymptomatic cases in theTSCgroup as compared
to the groupwithout TSC, but could be a chance ¢nding.
There was a wide range of presentation in all four
groups. The commonest presenting symptoms were
pneumothorax and dyspnoea.Other symptoms includedchronic dry cough, haemoptysis, wheeze and chest pain.
Development of cyanosis, respiratory failure and cor-
pulmonalewas also common.
Lung function tests show a wide range of patterns
from normal to obstructive through a mixed picture to
restrictive. This variation is unsurprising when the un-
derlying pathogenesis is considerly. Initially there is pro-
liferation of smooth muscle cells around the bronchi
leading to narrowingof the lumen, as seen in asthma,giv-
ing rise to an obstructive picture. However unlike asth-
ma the narrowing is notdue to bronchospasmbutrather
hyperplasia, and the obstruction is notreadily reversible.
With time air trapping in the alveoli leads to an emphy-
sematous picture with the formation of cysts and bullae
giving rise to a restrictive picture. As the disease pro-
gresses with more smooth muscle cells surrounding
both the airways and thebloodvessels di¡usionbecomes
impaired, cor-pulmonale and respiratory failure develop.
PatientswithTSCwere less likely to have their lung func-
tion tested than other su¡erers of LAM, possibly be-
cause about half of patients with TSC have severe
learning di⁄culties and might be unable to co-operate
with testing. Although there appeared to be di¡erences
between the two groups in terms of lung functionwith a
higher proportion of patients without TSC having a
mixedpicture. 25 of these patients were from one study
which might have used di¡erent criteria for measure-
ment to other studies.
Again, because of the rarity of this condition few stu-
dies havebeenperformed to assess long-term treatment
and indeed few therapeutic measures have been under-
taken in order to ameliorate the course of the disease.
Instead treatment is symptomatic.The presence of hor-
monc receptors in the lung tissue of patients with LAM
and TSC (16), the suggestion that exacebations can occur
at times of hormonal £uctuation, for example during
pregnancy and in associationwith the oral contraceptive
pill, and the relative absence of LAM in males have, not
surprisingly, led to attempts to ameliorate the disease by
hormonalmanipulation (17^20).Of cases reported in the
literature review under half received hormonal therapy
with inconsistent results. The best results appear to be
seen in those LAM patients who have TSC. Approxi-
matelyone-third (6/18) of patientswithTSC triedon hor-
monal therapy showed improvement compared with
none (0/25) showing improvement without hormonal
treatment. In 1989 Eliasson et al. (5) undertook a meta-
analysis of the hormonal treatment of LAM.They identi-
¢ed 30 cases of LAM treated by hormonalmanipulation.
It is not clear if any of the thirty cases reviewed su¡ered
fromTSC and it is not yetknownwhether LAMwithTSC
and Lam without TSC are similar in their response to
treatment.Unfortunatelymanyof the cases lacked infor-
mation ondosage, timing andduration of therapymaking
them ineligible for inclusion in the analysis (seeTable 3).
The remaining studies showed oophorectomy alone or
TABLE 3 Reportedregimens oftreatment before and aftermeta-analysis
Hormonal theraphy Claimed success Cases excluded* Objective success
Progesterone alone 8/13 5 5/9
Oophrectomyalone 5/9 2 5/7
Tamoxifen alone 2/7 4 1/3
Androgen alone 0/1 0 0/1
Oophrectomy+progesterone 3/5 3 2/2
Oophrectomyand tamoxifen 0/1 1 0
Progesterone+tamoxifen 1/2 2 0
Oophrectomy, progesterone+Tamoxifen 1/3 1 1/2
*In sequential evaluation of each case,10 caseswere excluded because therapy was started too late in the course of disease;
six additional caseswere excluded due to lackof data on dosage; of cases remaining, twowere excluded due to insu⁄cientdata
to judge outcome oftherapy.
LYMPHANGIOLEIOMYOMATOSIS: AREVIEWOF THELITERATURE 5in combination with progesterone to be the most suc-
cessful therapeutic option, with seven out of nine cases
showing stabilization or improvement. Progesterone
alonewas successful in ¢ve out of nine patients.None of
the other regimes showed any signi¢cant bene¢t.
Although this review suggests that hormonal manipula-
tionmightbebene¢cial in somepatients the results need
to be treated with caution.We would not recommend
radioablation of the ovaries as a means of hormonal ma-
nipulation in patientswithTSC: the genes involved inTSC
are tumour suppressor genes so there is a theoretical
risk that exposure to radiotherapy may increase the
incidence and development of hamartomas.
It was previously thought that there was a relentless
and severe deterioration after the onset of the disease.
Average duration of survival was reported to be 4?8
years in 1971 (2). More recent studies estimate survival
to be nearer to 10 years and there are even reports of
apparent spontaneous resolution. Unfortunately few of
the studies inwhich hormonal treatmentwas not under-
taken gave follow-up information on their patients mak-
ing it di⁄cult to summarize the natural history of this
condition.
LAM is undoubtedly rare and no study has attempted
to estimate its prevalencewithin the general population.
Although estimations have been made for its prevalence
within the TSC population they have been made on
biased groups and have not accounted for asymptomatic
and possibly milder cases. LAM is a disease of women of
child bearing age and a diagnosis of LAM in males and
children should be treated with caution and should be
con¢rmedbyHRCTas aminimum andpreferablyby lung
biopsy. Although the age of onset and age to diagnosis did
not vary within the groups, theTSC patients did show a
trend of presenting in a more insidious fashion with gra-
dual onset of increasing dyspnoea as compared to the
non-TSC patients who weremore likely to present with
a pneumothorax. Patients withTSCwere also less likely
to su¡er chylothoraces.The reasons for these di¡erence
are notclear but theymayre£ect slightdi¡erences in thegenetic pathogenesis of the two groups. It is di⁄cult to
summarise the natural history of this condition as there
are no large cohort studies, but it does appear to be ex-
tremely variable. Likewise treatment regimes have var-
ied greatly with poor long-term follow-up. Further
research is required not only to elicit the natural history
of this disease in greater detail, but also to determine the
optimum treatment regime. This is likely to require a
national surveillance programme.
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